# NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes

> **NCT04945330** · — · RECRUITING · sponsor: **Bayer** · enrollment: 100 (estimated)

## Conditions studied

- Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion

## Interventions

- **DRUG:** Larotrectinib (Vitrakvi, BAY2757556)

## Key facts

- **NCT ID:** NCT04945330
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2021-11-05
- **Primary completion:** 2029-06-30
- **Final completion:** 2029-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04945330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04945330, "NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04945330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*